Manuel Cano

Publications (6)6.9 Total impact

• Article: Drug-eluting stents vs. bare-netal stents in saphenous vein graft lesions.

  Carlos A Collet, J. Ribamar Costa Junior, Amanda G. M. R Sousa, Fausto Feres, Adriana Moreira, Ricardo Costa, Rodolfo Staico, Alejandro Almeida, Dimytri Siqueira, Manuel Cano, Galo Maldonado, Alexandre Abizaid, J. Eduardo. Sousa
  Revista Brasileira de Cardiologia Invasiva 01/2011; 19(2):122-130.
• Article: Drug eluting stents for the treatment of small vessels: very late experience (Up to 7 years) of the DESIRE Registry.

  Ederlon Ferreira Nogueira, Amanda G. M. R Sousa, J. Ribamar Costa Júnior, Adriana Moreira, Ricardo Costa, Galo Maldonado, Cantídio Campos, Manuel Cano, J. Eduardo. Sousa
  Revista Brasileira de Cardiologia Invasiva 01/2010; 18(3):288-293.
• Article: Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry.

  J Ribamar Costa, Amanda Sousa, Adriana C Moreira, Ricardo A Costa, Manuel Cano, Galo Maldonado, Cantídio Campos, Mariana Carballo, Ricardo Pavanello, J Eduardo Sousa
  [show abstract] [hide abstract]
  ABSTRACT: Our aim was to access the incidence of late major adverse cardiac events (MACE) and stent thrombosis (ST) in nonselected, complex patients followed for a period >/=4 years. Despite the efficacy of drug-eluting stents (DES) in reducing repeated target lesion revascularization, concerns regarding the occurrence of late and very late ST have partially obscured the benefits of this novel technology. All consecutive patients treated solely with DES between May 2002 and January 2005 were enrolled into this prospective, nonrandomized, single-center registry. The primary end point was long-term occurrence of MACE up to 7 years. Independent predictors of MACE, cardiac death, target lesion revascularization, and ST were obtained by a multivariate Cox proportional hazards regression model. A total of 1,010 patients were enrolled. Most of them were men (77%) with a mean age of 63.7 years. Stent/patient rate was 1.4. Patients were kept in dual antiplatelet therapy for 3 and 6 months after Cypher (Cordis, Johnson & Johnson, Miami Lakes, Florida) and Taxus (Boston Scientific Corp., Natick, Massachusetts) stent implantation, respectively. Follow-up was obtained in 98.2% of the cohort (median 5.01 years). Survival free of MACE and cumulative incidence of definite/probable ST were 84.6% and 1.7%, respectively. Independent predictors of ST were percutaneous coronary intervention in the setting of acute myocardial infarction, DES overlapping, treatment of multivessel disease, presence of moderate-to-severe calcification at lesion site, and in-stent residual stenosis. The deployment of DES in complex, real-world patients resulted in a low rate of very long-term MACE and ST. However, ST still occurs very long after the index procedure.
  01/2010; 3(1):12-8. · 1.07 Impact Factor
• Source

  Available from: Ibraim Masciarelli F Pinto

  Article: Intervenção Coronária Percutânea em Pontes de Veia Safena com Uso de Stents Farmacológicos: Resultados Agudos e Tardios dos Pacientes Incluídos no …

  Jose De Ribamar, Amanda G M R Sousa, Adriana Moreira, Ricardo Costa, Galo Maldonado, Manuel Cano, Ibraim Pinto, Cantídio Campos, Rodolfo Staico, Fausto Feres, Maria Helena Dib, Ricardo Pavanello, J Eduardo Sousa, Artigo Original, J Eduardo Correspondência, Sousa, Desembargador Rua, Eliseu
  01/2009; 17:202-8.
• Article: Long-term clinical outcomes of the Drug-Eluting Stents in the Real World (DESIRE) Registry.

  Amanda Sousa, J Ribamar Costa, Adriana C Moreira, Manuel Cano, Galo Maldonado, Ricardo A Costa, Ricardo Pavanello, Edson R Romano, Cantidio Campos, Nagib Haddad, Alexandre Abizaid, Fausto Feres, Luiz Alberto Mattos, Rodolfo Staico, J Eduardo Sousa
  [show abstract] [hide abstract]
  ABSTRACT: Recently, cardiologists have treated more complex patients and lesions with drug-eluting stents (DES). However, long-term efficacy and safety of the off-label use of these new devices is yet to be demonstrated. The Drug-Eluting Stents in the Real World (DESIRE) registry is a prospective, nonrandomized single-center registry with consecutive patients treated solely with DES between May 2002 and May 2007. The primary end-point was long-term occurrence of major adverse cardiac events (MACE). Patients were clinically evaluated at 1, 3, and 6 months and then annually up to 5 years. A total of 2,084 patients (2,864 lesions and 3,120 DES) were included. The mean age was 63.8 +/- 11.5 years. Diabetes was detected in 28.9% and 40.7% presented with acute coronary syndrome. Cyphertrade mark was the predominant DES in this registry (83.5%). Mean follow-up time was 2.6 +/- 1.2 years and was obtained in 96.5% of the eligible patients. Target lesion revascularization (TLR) was performed in 3.3% of the patients. Q wave myocardial infarction (MI) occurred in only 0.7% of these patients and total stent thrombosis rate was 1.6% (n = 33). Independent predictors of thrombosis were PCI in the setting of MI (HR 11.2; 95% CI, 9.6-12.4, P = 0.001), lesion length (HR 4.6; 95% CI, 3.2-5.3, P = 0.031), moderate to severe calcification at lesion site (HR 13.1; 95% CI, 12.1-16.7, P < 0.001), and in-stent residual stenosis (HR 14.5; 95% CI, 10.2-17.6, P < 0.001). The use of DES in unselected population is associated with long-term safety and effectiveness with acceptable low rates of adverse clinical events.
  Journal of Interventional Cardiology 09/2008; 21(4):307-14. · 1.18 Impact Factor
• Article: Drug-eluting stents vs bare metal stents for the treatment of large coronary vessels.

  Arturo R Quizhpe, Fausto Feres, José de Ribamar Costa, Alexandre Abizaid, Galo Maldonado, Ricardo Costa, Andrea Abizaid, Manuel Cano, Adriana C Moreira, Rodolfo Staico, Luiz Alberto Mattos, Luiz Fernando Tanajura, Aurea Chaves, Marinella Centemero, Amanda M R Sousa, J Eduardo M R Sousa
  [show abstract] [hide abstract]
  ABSTRACT: Lately drug-eluting stents (DES) have dramatically reduced restenosis rates and need for repeat revascularization in a wide subset of lesion and patients. However, their benefit for the treatment of large vessels (> 3.0 mm) has yet to be established. We investigated whether DES are superior to bare metal stents (BMS) in terms of clinical outcomes for the treatment of large coronary vessels. This study assessed the long-term outcomes (cardiac death, acute myocardial infarction, and need for repeat intervention in the treated vessel) of patients treated with either a DES (Cypher and Taxus) or a BMS of > or = 3.5 mm in diameter. A total of 250 consecutive patients who underwent DES implantation were clinically followed for 1 year and compared to 250 patients who were treated with BMS. Interventions in the setting of acute ST elevation myocardial infarction and treatment of bypass grafts were excluded. Cypher was the DES deployed in 70.8% of cases. Most of the enrolled patients were men (78%) with single vessel disease (65.6%). The left anterior descending artery was the culprit vessel in 34.2% of cases. Bare metal stent and DES cohorts had equivalent interpolated reference vessel diameter (3.19 +/- 0.3 mm for BMS vs 3.18 +/- 0.2 for DES; P = .1). Lesion was significantly longer in the group treated with DES (13.4 +/- 5.1 mm for BMS group vs 14.3 +/- 3.5 for DES; P = .0018). After 1 year of clinical follow-up, 95.2% of patients treated with DES and 91.2% of the patients who received BMS were free of major events (P = .2). A trend toward higher target-lesion revascularization was noticed in the group treated with BMS (4.8% vs 1.6%; P = .07). Percutaneous treatment of large coronary vessels carries a low risk of clinical events irrespective of the type of stent used.
  American heart journal 09/2007; 154(2):373-8. · 4.65 Impact Factor